We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Stool Test Could Help Pinpoint IBD Diagnosis

By LabMedica International staff writers
Posted on 19 Jan 2026

Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. More...

Diagnosis and disease monitoring often depend on colonoscopy, an invasive and costly procedure that many patients undergo repeatedly. Existing stool tests measure general inflammation markers and cannot reliably pinpoint whether inflammation originates in the gut. Researchers have now developed a tool that directly detects gut-specific immune activity in fecal samples, offering a more precise and less invasive approach.

In the research led by the University of Edinburgh (Scotland, UK), investigators focused on granzyme A (GzmA), an enzyme released by overactive T cells that are known to drive tissue damage and inflammation in IBD. After identifying elevated GzmA levels in inflamed intestinal tissue from IBD patients, the team designed an optical luminescent reporter that emits light when it detects GzmA activity.

The reporter produces stronger light signals when enzyme activity is higher, allowing inflammation levels to be quantified directly from stool samples. Unlike conventional fecal tests that measure indirect markers such as calprotectin, this approach targets a molecule closely linked to immune-driven gut inflammation. The tool is designed to be fast, sensitive, and compatible with non-invasive stool testing workflows.

The luminescent reporter was tested on 150 stool samples from both IBD patients and healthy individuals. When combined with standard fecal calprotectin testing, the new method identified IBD more accurately than calprotectin alone. The findings, published in the journal Gut, demonstrate that measuring GzmA activity provides additional, disease-relevant information.

Researchers suggest that the ability to detect gut-specific immune activity could reduce unnecessary colonoscopies and enhance diagnostic confidence. The tool could also support personalized treatment by enabling rapid monitoring of inflammation levels in response to therapy. Further validation studies are planned before the approach can be translated into routine clinical use.

“The speed and sensitivity of our optical tool has the potential to accelerate future studies into the roles of the immune system in IBD, as well as improving the pathway to diagnosis,” said Professor Marc Vendrell, study lead. “In the future, these optical tools could also be used to help tailor treatments for IBD patients.”

Related Links:
University of Edinburgh


New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Hematology Consumables
Bioblood Devices
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.